Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Consensus Recommendation of “Hold” by Analysts

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) have been given an average rating of “Hold” by the five analysts that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.25.

CALT has been the topic of several recent analyst reports. HC Wainwright restated a “neutral” rating and set a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital cut shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. Citigroup reiterated a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Jefferies Financial Group restated a “hold” rating and issued a $39.00 target price (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Trading Up 1.7 %

CALT opened at $40.41 on Wednesday. Calliditas Therapeutics AB has a fifty-two week low of $15.25 and a fifty-two week high of $41.90. The firm has a market capitalization of $1.20 billion, a PE ratio of -21.84 and a beta of 1.77. The company has a debt-to-equity ratio of 8.46, a current ratio of 2.69 and a quick ratio of 2.62. The company’s 50-day moving average is $38.95 and its 200 day moving average is $28.72.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The firm had revenue of $52.36 million during the quarter, compared to the consensus estimate of $42.89 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. During the same period in the prior year, the business posted ($0.33) earnings per share. As a group, research analysts predict that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.